Home/Small Molecules/Neuroscience

Neuroscience

Neurotransmission, neural targets and neurological research.

Browse all research categories

Browse by research category

Products may appear in more than one category. Counts refer to distinct catalog numbers within each category.

Other Research Tools (75) · Additional reagents, building blocks and specialized research tools.

Neuroscience products

Combine a keyword, research category and target to narrow the product list.

Loading catalog filters…

793 products · Showing 529–576

DC26042

MLS-1547

CAS 315698-36-3

MLS-1547 is a G protein-biased agonist of dopamine D2 receptors (EC50 = 0.37 μM in a calcium mobilization assay).It inhibits forskolin-induced cAMP accumulation in CHO cells expressing human D2 receptors (EC50 = 0.26 μM) but is inactive in β-arrestin recruitment assays. MLS-1547 antagonizes dopamine-induced β-arrestin recruitment in cell-based assays with IC50 values ranging from 3.8 to 9.9 μM.It is also an inhibitor of type II secretion in Gram-negative bacteria.MLS-1547 inhibits secretion of phospholipase C (PlcH/N) and the virulence factor elastase (LasB) from P. aeruginosa (IC50s = 15 and 13 μM, respectively) and inhibits B. pseudomallei protease secretion by 90.8% when used at a concentration of 25 μM.

MLS-1547 chemical structure
DC23215

Methoxy-PEPy

CAS 524924-76-3

Methoxy-PEPy is a potent, selective mGlu5 receptor antagonist with IC50 of 1 nM; exhibits 14-fold higher binding in forebrain relative to cerebellum in mGlu5 receptor-deficient mice, the radioligand [3H]methoxy-PEPy is useful for determining the occupancy of mGlu5 receptors in the brain.

Methoxy-PEPy chemical structure
DC9006

Lamotrigine

CAS 84057-84-1

Lamotrigine(BW430C) is a novel anticonvulsant drug for inhibition of 5-HT and sodium channel.Lamotrigine stabilises presynaptic neuronal membranes by blockade of voltage-dependent sodium channels, thus preventing the release of excitatory neurotransmitters, particularly glutamate and aspartate. In rat cerebral cortex tissue incubated with veratrine 10 mg/L, lamotrigine is twice as potent in inhibiting the release of glutamate and aspartate (ED 50 = 5.38 mg/L for each) than the release of GABA (ED50 = 11.2 mg/L), and is much less potent in inhibiting acetylcholine release (ED50 = 25.6 mg/L) when cortical slices is exposed to veratrine 75 mg/L. Basal glutamate release is unaffected. Lamotrigine inhibits high-frequency sustained repetitive firing of sodium-dependent action potentials, indicating a direct effect on voltage-activated sodium channels. Lamotrigine (Lamictal), a phenyltriazine derivative, is a well established anticonvulsant agent that has shown efficacy in the prevention of mood episodes in adult patients with bipolar I disorder. lamotrigine significantly delayed time to intervention for a depressive episode and showed limited efficacy in delaying time to intervention for a manic/hypomanic episode, compared with placebo. Lamotrigine is generally well tolerated.

Lamotrigine chemical structure
DCAPI1055

Iloperidone (Fanapt)

CAS 133454-47-4

For the detailed information of Iloperidone (Fanapt), the solubility of Iloperidone (Fanapt) in water, the solubility of Iloperidone (Fanapt) in DMSO, the solubility of Iloperidone (Fanapt) in PBS buffer, the animal experiment(test) (test) of Iloperidone (Fanapt), the cell expriment (test) of Iloperidone (Fanapt), the in vivo, in vitro and clinical trial test of Iloperidone (Fanapt), the EC50, IC50,and Affinity of Iloperidone (Fanapt),, please contact DC Chemicals.

Iloperidone (Fanapt) chemical structure
DC9451

Flumazenil

CAS 78755-81-4

Flumazenil(Ro 15-1788) is a benzodiazepine antagonist, non-selective for α1, α2, α3 or α5-containing GABAA receptors. Centrally active upon systemic administration in vivo. Flumazenil, an imidazobenzodiazepine derivative, antagonizes the actions of benzodiazepines on the central nervous system. Flumazenil competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in humans.

Flumazenil chemical structure
DC9133

Domperidone

CAS 57808-66-9

Domperidone is a dopamine blocker and an antidopaminergic reagent.Domperidone is a useful alternative to metoclopramide for treatment of gastroparesis due to better tolerability. Effectiveness and side-effects from domperidone may be influenced by patient-related factors including polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and domperidone targets. Domperidone is a dopamine D(2) receptor antagonist, which has been used as antiemetic agent in human beings. The percentage recovery of domperidone from wastewater was 95.0%. Celiprolol was used as the internal standard to access the percentage extraction of domperidone from wastewater. Domperidone, a dopamine antagonist that does not easily cross the blood-brain barrier, is considered the gold standard for treating gastrointestinal symptoms in patients with Parkinson's disease (PD) because the risk of developing extrapyramidal adverse effects is considered minimal.

Domperidone chemical structure
DC9067

Clozapine

CAS 5786-21-0

Clozapine(HF 1854) is a 5-HT2A/2C and dopamine receptor blocker with Ki values of 21, 170, 170, 230 and 330 nM for D4, D3, D1, D2 and D5 receptors respectively.Clozapine is atypical antipsychotic drug, with a much lower tendency to cause extrapyramidal side effects than conventional neuroleptics. Clozapine displays a broad range of pharmacological actions; the antipsychotic effects are thought to be mediated principally by 5-HT2A/2C and dopamine receptor blockade (Ki values are 21, 170, 170, 230 and 330 nM for D4, D3, D1, D2 and D5 receptors respectively).

Clozapine chemical structure
DC9081

Clomipramine HCL

CAS 17321-77-6

Clomipramine HCl is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively.Clomipramine hydrochloride (Anafranil) is a hydrochloride salt of clomipramine which is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively. Clomipramine hydrochloride (Anafranil) is a tricyclic antidepressant. Clomipramine hydrochloride (Anafranil) is a norepinephrine-reuptake inhibitor and is an antiobsessional drug. Clomipramine hydrochloride (Anafranil) is an antagonist/inverse agonist at the following receptors: D2 receptor (Ki = 162 nM), D3 receptor (Ki = 30 nM), α1-adrenergic receptor (Ki = 3.2 nM), α2-adrenergic receptor (Ki = 525 nM), H1 receptor (Ki = 31 nM), mACh receptors (Ki = 37 nM), 5-HT2A receptor (Ki = 36 nM), 5-HT2C receptor (Ki = 65 nM), 5-HT3 receptor (Ki = 85 nM), 5-HT6 receptor (Ki = 54 nM), 5-HT7 receptor (Ki = 127 nM), D1 receptor (Ki = 219 nM).

Clomipramine HCL chemical structure
DC12304

Clocapramine hydrochloride hydrate (3-Chlorocarpipramine hydrochloride hydrate)

CAS 60789-62-0

In Vivo Clocapramine shows the lowest potency for D2-occupancy in vivo. An in vivo receptor binding technique is used to evaluate the binding profiles of typical and atypical antipsychotic drugs to striatal dopamine-D2 and frontal serotonin-5-HT2 receptors in a rat brain using more specific ligands. Clocapramine produces ratios of potency in occupying 5-HT2 versus D2 receptors that fall between these two groups (ED50 of 14.5 mg/kg for D2, 4.9 mg/kg for 5-HT2).

Clocapramine hydrochloride hydrate (3-Chlorocarpipramine hydrochloride hydrate) chemical structure
DC12100

Cirsimaritin

CAS 6601-62-3

In Vivo Cirsimaritin significantly reduces the anxiety in mice. Cirsimaritin does not decrease by co-administration of flumazenil (2.5 mg/kg) with salvigenin, rosmanol and cirsimaritin (10 mg/kg), indicating that the high-affinity benzodiazepine binding site is not involved in the anxiolytic activity induced by these compounds.

Cirsimaritin chemical structure
DC7087

Blonanserin(AD-5423)

CAS 132810-10-7

Blonanserin is a novel atypical antipsychotic agent with potent dopamine D2 (Ki, 14.8 nM) and serotonin 5-HT2(Ki, 3.98 nM) receptors antagonist properties.For the detailed information of Blonanserin(AD-5423), the solubility of Blonanserin(AD-5423) in water, the solubility of Blonanserin(AD-5423) in DMSO, the solubility of Blonanserin(AD-5423) in PBS buffer, the animal experiment (test) of Blonanserin(AD-5423), the cell expriment (test) of Blonanserin(AD-5423), the in vivo, in vitro and clinical trial test of Blonanserin(AD-5423), the EC50, IC50,and Affinity of Blonanserin(AD-5423), Please contact DC Chemicals.

Blonanserin(AD-5423) chemical structure
DC9426

B-HT 920

CAS 36085-73-1

B-HT 920(Talipexole 2Hcl) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity. in vitro: N/A in vivo: Intravenous injection of 30 micrograms/kg of B-HT 920 into cats lead initially to an increase in blood pressure and then to a long-lasting decrease in blood pressure and heart rate. Vagally mediated reflex bradycardia elicited by angiotensin injection in beta-adrenoceptor-blocked dogs was facilitated by intracisternal injection of 10 micrograms/kg B-HT 920.

B-HT 920 chemical structure
DC8976

Aniracetam

CAS 72432-10-1

Aniracetam(Ro 13-5057) is a nootropics and neuroprotective drug, which is selectively modulates the AMPA receptor and nAChR.Aniracetam is an ampakine and nootropic of the racetam chemical class purported to be considerably more potent than piracetam. It selectively modulates the AMPA receptor. It is lipid soluble and has possible cognition enhancing effects. It has been tested in animals extensively, Alzheimer's patients and temporarily-impaired healthy subjects. It has shown potential as an anxiolytic in three clinical animal models. Administration of aniracetam for 10 days (post-natal days (PND) 18-27), at a dose of 50 mg/kg reversed cognitive deficits in both rat genders, indicated by a significant increase in the number of avoidances and the number of 'good learners'. After the termination of the nootropic treatment, a significant increase in both amplitude and frequency of AMPA receptor-mediated mEPSCs in hippocampal CA-1 pyramidal cells was observed.

Aniracetam chemical structure
DC3171

Agomelatine

CAS 138112-76-2

Agomelatine (trade names Valdoxan, Melitor, Thymanax) is an antidepressant developed by the pharmaceutical company Servier. It is marketed For the treatment of major depressive disorder and has been reported to have a reduced level of sexual side effects as well as discontinuation effects compared to some other antidepressants. Agomelatine may also have positive effects on sleep. For the detailed information about the solubility of Agomelatine in water, the solubility of Agomelatine in DMSO, the solubility of Agomelatine in PBS buffer, the animal experiment(test) of Agomelatine,the in vivo,in vitro and clinical trial test of Agomelatine,the cell experiment(test) of Agomelatine,the IC50, EC50 and Affinity of Agomelatine, please contact DC Chemicals.

Agomelatine chemical structure
DC9026

Afloqualone

CAS 56287-74-2

Afloqualone is a agonist of GABA receptor .Afloqualone is an analogue of methaqualone. It has sedative and muscle-relaxant effects, resulting from its agonist activity at the β subtype of the GABAa receptor. in vivo: Afloqualone slightly increased the response during the alarm period in one out of 3 rats at 5, 10, and 20 mg/kg p.o., respectively.

Afloqualone chemical structure
DC9324

Adoprazine

CAS 222551-17-9

Adoprazine, a potential atypical antipsychotic bearing potent D2 receptor antagonist and 5-HT1A receptor agonist properties. Adoprazine is a full 5-HT1A receptor agonist and full D2/3 receptor antagonist possessing characteristics of an atypical antipsychotic, representing a potential novel treatment for schizophrenia.

Adoprazine chemical structure
DC23202

JNJ-16259685

CAS 409345-29-5

aA highly potent, selective, non-competitive and centrally active mGluR1 antagonist with Ki of 0.34 nM; shows no agonist, antagonist or PAM activity toward rat mGlu2/3/4/6 receptors (IC50>10 uM) and does not bind to AMPA, NMDA receptor and other neurotransmitter receptors; inhibits glutamate-induced Ca2+ mobilization for rat and human mGluR1 with IC50 of 3.24 and 1.21 nM, inhibits glutamate-mediated inositol phosphate production with IC50 of 1.73 nM; attenuates drug context-induced reinstatement of cocaine seeking in rats.

JNJ-16259685 chemical structure
DC22524

ZSET1446

CAS 887603-94-3

A small molecule cognitive enhancer that potentiates acetylcholine-mediated facilitation of inhibitory synaptic transmission in the hippocampal neurons; increases the extracellular ACh in the cortex and hippocampus and enhances nicotine-stimulated ACh release in the hippocampus in normal rats, without affecting nAChRs.Alzheimer's DiseasePhase 2 Discontinued

ZSET1446 chemical structure
DC23958

MRK-016

CAS 342652-67-9

A potent, functionally selective, CNS-penetrating and orally bioavailable inverse agonist of benzodiazepine site of GABAA α5 receptor with Ki of 0.8-1.5 nM for α1-, α2-, α3-, andα5-containing GABAA receptors; has inverse agonist efficacy selective for the α5 subtype, increases long-term potentiation in mouse hippocampal slices; enhances performance in animal models of cognition, does not exhibit the convulsant, proconvulsant, or anxiogenic activity associated with nonselective GABAA inverse agonists.

MRK-016 chemical structure
DC22389

Metoclopramide

CAS 364-62-5

A potent dopamine D2 receptor antagonist with Ki of 28 nM; also is a mixed 5-HT3 receptor antagonist/5-HT4 receptor agonist; commonly used to treat nausea and vomiting caused by chemotherapy.Chemotherapeutic AgentsPhase 2 Discontinued

Metoclopramide chemical structure
DC22382

SB-277011

CAS 215803-78-4

A potent and selective dopamine D3 receptor antagonist with pKi of 8.0; displays >100-fold selectivity against the D2, 5-HT1B, and 5-HT1D receptors; exhibits high oral bioavailability and brain penetration in rats.SchizophreniaDiscontinued

SB-277011 chemical structure
DC20150

5-Methoxyflavone

CAS 42079-78-7

In Vitro 5-Methoxyflavone (compound 1) is identified as a candidate compound endowed with the ability to inhibit DNA pol-β in multiple and to prevent cell-cycle initiation and subsequent neuronal apoptosis in Aβ-challenged primary neuronal cultures. 5-methoxyflavone (10-30 μM) is able to significantly enhance toxicity of MMS on 92TAg cells. 5-Methoxyflavone (1 or 10 μM) significantly reduces polymerase activity on a gapped substrate. 5-Methoxyflavone (5-MF, 0-100 μg/mL) results in a time dependent reduction in the levels of antiapoptotic proteins cFLIP, Mcl-1 and an increase in the proapoptotic protein BAX. 5-MF induces both TRAIL-R1(DR4) and TRAIL-R2 (DR5) in a time-dependent manner. In Vivo 5-Methoxyflavone (100, 150 mg/kg, i.p) significantly decreases the latency time to loss of righting reflex. 5-Methoxyflavone (50, 100 and 150 mg/kg, i.p) exhibits a significant and dose-dependent reduction in the spontaneous locomotor activity. 5-Methoxyflavone (50, 100 mg/kg, i.p) reduces the rearing response. 5-Methoxyflavone (100, 125 and 150 mg/kg, i.p) completely abolishesed the grooming response similar to diazepam treated animals.

5-Methoxyflavone chemical structure
DC8159

L-701,324

CAS 142326-59-8

L-701324 is an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.Target: NMDA ReceptorL-701324 is a potent, active anticonvulsant with a reduced propensity to activate mesolimbic dopaminergic systems in rodents. L-701324 exhibits a beneficial action in the animal model of parkinsonian rigidity, but not that of parkinsonian akinesia. L-701324 (2.5-40 mg/kg, i.p.) dose-dependently decreased the muscle tone enhanced by haloperidol (1-5 mg/kg, i.p.).

L-701,324 chemical structure
DC21689

SR 142948A

CAS 184162-21-8

A potent, selective and orally active neurotensin receptor antagonist with IC50 of 1.19 nM; antagonizes neurotensin-induced inositol monophosphate formation in HT 29 cells with IC50 of 3.9 nM, inhibits the turning behavior induced by neurotensin in mice, completely antagonizes neurotensin-evoked acetylcholine release in the rat striatum at 0.1 mg/kg; also blocks both hypothermia and analgesia induced by i.c.v. injection of neurotensin injection into the ventral tegmental area.

SR 142948A chemical structure
DC23191

ZL-006

CAS 1181226-02-7

ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.

ZL-006 chemical structure
DC21392

NNC-711

CAS 145645-62-1

NNC-711 is a potent and selective inhibitor of GABA uptake by GAT-1 with IC50 of 0.04 uM; displays excellent selectivty over rGAT-2, hGAT-3 and hBGT-1, and other other neurotransmitter receptors; inhibits synaptosomal (IC50=47 nM), neuronal (IC50=1238 nM) and glial (IC50=636 nM) GABA uptake in vitro; demonstrates potent anticonvulsant activity against rodent seizures induced by DMCM.

NNC-711 chemical structure
DC8878

SB 242084

CAS 181632-25-7

SB 242084 is a potent and selective antagonist of 5-HT2C receptor. It increases the basal activity of dopaminergic neurons and affects the behavioral responses mediated by 5-HT2C such as mesolimbic neuron activity and food intake.

SB 242084 chemical structure
DC4239

Flupirtine maleate

CAS 75507-68-5

For the detailed information about the solubility of Flupirtine maleate in water, the solubility of Flupirtine maleate in DMSO, the solubility of Flupirtine maleate in PBS buffer, the animal experiment(test) of Flupirtine maleate,the in vivo,in vitro and clinical trial test of Flupirtine maleate,the cell experiment(test) of Flupirtine maleate,the IC50, EC50 and Affinity of Flupirtine maleate, please contact DC Chemicals.

Flupirtine maleate chemical structure
DC10363

Coumestrol

CAS 479-13-0

Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC50 of 50 μM.

Coumestrol chemical structure
DC8289

Prucalopride succinate

CAS 179474-85-2

Prucalopride succinate is a selective, high affinity 5-HT4 receptor agonist with pKi of 8.6/8.1 for 5-HT4a/4b.in vitro: Prucalopride was a 5-HT(4) receptor agonist in the guinea-pig colon, as it induced contractions (pEC(50)=7.48+/-0.06; insensitive to a 5-HT(2A) or 5-HT(3) receptor antagonist, but inhibited by a 5-HT(4) receptor antagonist) as well as the facilitation of electrical stimulation-induced noncholinergic contractions (blocked by a 5-HT(4) receptor antagonist). Prucalopride did not cause relevant inhibition of 5-HT(2A), 5-HT(2B), or 5-HT(3), motilin or cholecystokinin (CCK(1)) receptor-mediated contractions, nor nicotinic or muscarinic acetylcholine receptor-mediated contractions, up to 10 microM. in vivo: Rat microdialysis studies revealed that prucalopride maximally increased ACh and histamine levels in the prefrontal cortex at 5 and 10 mg/kg, whereas PRX-03140 significantly increased cortical histamine levels at 50 mg/kg, failing to affect ACh release at doses lower than 150 mg/kg. For the detailed information of Prucalopride succinate, the solubility of Prucalopride succinate in water, the solubility of Prucalopride succinate in DMSO, the solubility of Prucalopride succinate in PBS buffer, the animal experiment (test) of Prucalopride succinate, the cell expriment (test) of Prucalopride succinate, the in vivo, in vitro and clinical trial test of Prucalopride succinate, the EC50, IC50,and affinity,of Prucalopride succinate, For the detailed information of Prucalopride succinate, the solubility of Prucalopride succinate in water, the solubility of Prucalopride succinate in DMSO, the solubility of Prucalopride succinate in PBS buffer, the animal experiment (test) of Prucalopride succinate, the cell expriment (test) of Prucalopride succinate, the in vivo, in vitro and clinical trial test of Prucalopride succinate, the EC50, IC50,and affinity,of Prucalopride succinate, Please contact DC Chemicals.

Prucalopride succinate chemical structure
DC22622

WAY-100635

CAS 162760-96-5

A potent and selective 5-HT1A receptor antagonist; also acts as potent full agonist at the D4 receptor; completely prevents not only the hyperpolarization, with an IC50 of 1.3 nM, but also the decrease in membrane input resistance produced by 5-HT and 5-carboxamidotryptamine with IC50 of 22.5 μM and 50 nM, respectively. AnxietyPhase 1 Discontinued

WAY-100635 chemical structure
Browse target & topic index A–Z (366)
11β-HSD (1)15-PGDH (2)5-HT Receptor (16)Acetyl-CoA Carboxylase (ACC) (3)Acetylcholinesterase (AChE) (2)Ack1 (TNK2) (1)Acyltransferase (1)ADC Cytotoxin (6)ADCs Linker/Click Chemistry (5)Adenosine Receptor (9)Adenylate Cyclase (2)Adrenergic Receptor (11)Akt (12)Alcoholism (2)Aldehyde Dehydrogenase (ALDH) (6)Allergy (5)Alzheimer Disease (13)Aminopeptidase (1)AMPK (8)Amyloids (4)Anaplastic Lymphoma Kinase (ALK) (9)Androgen Receptor (AR) (11)Anemia (4)Angiotensin Receptor (4)Antibody/Protein labeling dyes (1)Antifolate (2)Anxiety (1)Apoptosis Inducer (3)Arginase (1)Arp2/3 complex (1)Aryl hydrocarbon Receptor (AhR) (1)Asthma (5)Atherosclerosis (2)ATM/ATR (8)Aurora Kinase (10)Autophagy (6)Autophagy-related Protein (Atg) (2)Autotaxin (2)Bacterial (26)Bacterial Infection (17)Bcl-2 (14)Bcr-Abl (5)BCRP (1)Beta-catenin (4)Beta-secretase (BACE) (4)Blood Cancer (91)BMI-1 (1)Bone Cancer (6)Brain Cancer (6)Breast Cancer (30)Bromodomain (22)BTK (10)c-Fms (CSF1R) (5)c-Fos/AP-1 (1)c-Kit (6)c-Met (HGFR) (11)c-Myc (2)Calcium Channel (4)Calcium-sensing Receptor (CaSR) (1)CaMK (4)Cannabinoid Receptor (6)Carbonic Anhydrase (1)Carboxypeptidase (1)Casein Kinase (6)Caspase (4)Cathepsin (6)Cdc2-like Kinase (CLK) (1)CETP (2)CFTR (7)Checkpoint Kinase (Chk) (8)Chemokine Receptor (CCR and CXCR) (14)Chemotherapeutic Agents (19)Chloride Channel (1)CMV (2)CMV Infection (2)Colon Cancer (9)Complement System (1)COPD (3)CREB/CBP (2)CRF Receptor (2)CRISPR/Cas9 (1)Cushing Disease (1)Cyclin-dependent Kinase (CDK) (39)Cyclooxygenase (COX) (4)Cytochrome P450 (CYPs) (5)Depression (2)Dermatitis (2)Deubiquitinase (DUB) (7)Diabetes (20)Dipeptidyl Peptidase (DPP) (3)Discoidin Domain Receptor (DDR) (1)DNA Alkylator/Crosslinker (10)DNA Methyltransferase (DNMT) (1)DNA Repair Protein (1)DNA-PK (2)DNA/RNA Synthesis (5)Dopamine beta-hydroxylase (1)Dopamine Receptor (7)Drug Metabolite (1)Drug-Linker Conjugates (11)Dyes (4)DYRK (1)Dyslipidemia (9)E3 Ligase Ligand (6)E3 Ligase Ligand-Linker Conjugate (1)E3 Ubiquitin Ligase (4)Ebola Virus Infection (1)EGFR (32)Elastase (2)Endothelin Receptor (5)Enzymes substrates (13)Epigenetic Reader Domain (3)Epilepsy (4)ERK (4)Estrogen Receptor/ERR (13)Eukaryotic Initiation Factor (eIF) (2)Exportin-1 (CRM1,XPO1) (2)FABP (1)Factor Xa (5)Farnesoid X Receptor (FXR) (5)Farnesyl transferase (FTase) (1)Ferroptosis (6)FGFR (15)Fibrosis (5)FLT3 (6)Focal Adhesion Kinase (FAK) (11)Foxo1 (1)Free Fatty Acid Receptor (FFAR) (5)Fungal (2)Fungal Infection (1)GABA Receptor (13)Galectin (1)Gastric Cancer (8)Ghrelin Receptor (GHSR) (3)Glucagon Receptor (4)Glucokinase (2)Glucose Transporter (GLUT) (2)Glutamate Transporter (2)GPCR (1)GPER (GPR30) (1)GPR139 (1)GPR183 (EBI2) (2)GPR39 (1)GPR55 (1)GPR84 (1)GRK (GPCRK) (2)Growth Hormone Deficiency (2)GSK-3 (8)Guanylate Cyclase (3)HBV (1)HBV Infection (1)HCN Channel (2)HCV (8)HCV Infection (9)HDAC (38)Heart Arrhythmia (2)Heart Failure (5)Heat Shock Protein (HSP) (15)Hedgehog (Hh) (1)HIF/HIF Prolyl-hydroxylase (8)Histamine Receptor (6)Histone Acetyltransferase (HAT) (5)Histone Demethylase (11)Histone Methyltransferase (HMTase) (31)HIV (12)HIV Infection (11)HMG-CoA Reductase (HMGCR) (3)HSV (1)HSV Infection (1)Hypercholesterolemia (1)Hyperparathyroidism (1)Hypertension (8)IAP (1)IGF-1R (3)iGluR (15)Indoleamine 2,3-Dioxygenase (IDO) (4)Infection (1)Influenza (6)Influenza Virus (6)Insulin Receptor (2)Integrin (6)Interleukin Receptor (1)IRAK (2)IRE1 (4)Irritable Bowel Syndrome (2)Ischemia (1)Isocitrate Dehydrogenase (IDH) (5)ITK (1)IκB kinase (IKK) (7)JAK (32)JNK (3)Keap1-Nrf2 (6)Kidney Cancer (10)Kinesin (5)Kruppel-like Factor (KLF) (1)Kynurenine 3-Monooxygenase (KMO) (1)Leukotriene Receptor (1)LIM Kinase (LIMK) (3)Lipids fragment (1)Liver Cancer (6)Liver X Receptor (LXR) (3)LRRK2 (9)Lung Cancer (39)Lysophospholipid Receptor (12)LYTACs (3)mAChR (9)MALT1 (2)MAP4K (1)Matrix Metalloproteinase (MMP) (10)MDM2-p53 (9)MEK (MAP2K) (14)MEKK (MAP3K) (1)Melanocortin Receptor (2)MELK (1)mGluR (7)MicroRNA (1)Microtubule/Tubulin (5)Mineralocorticoid Receptor (MLR) (1)MITF (1)Mixed Lineage Kinase (MLK) (3)MNK (2)Molecular Glues (13)Monoamine Transporter (5)Monocarboxylate Transporter (MCT) (1)Monopolar Spindle 1 (Mps1/TTK) (3)mTOR (13)Multiple Sclerosis (6)Myosin (1)Na-K-Cl Cotransporter (NKCC) (2)nAChR (2)NADPH Oxidase (NOX) (2)NAMPT (3)Natural products (37)Neprilysin (1)Neurokinin Receptor (3)Neuropeptide Y Receptor (3)NF-κB (5)Nitric Oxide Synthase (NOS) (1)NOD-like Receptor (NLR) (3)Notch (2)Nucleoside Antimetabolite/Analog (10)Nur77 (NR4A1) (1)Obesity (1)Oct3/4 (1)Opioid Receptor (5)Orexin Receptor (7)Osteoporosis (2)Ovarian Cancer (14)Oxytocin Receptor (OXTR) (2)P-glycoprotein (P-gp) (3)p21-activated Kinase (PAK) (1)P2X Receptor (2)P2Y Receptor (1)p38 MAPK (10)p97/VCP (1)Pain (12)Pancreatic Cancer (10)Parasite (5)Parasite Infection (2)Parkinson Disease (2)PARP (19)PCSK9 (1)PD-1/PD-L1 (4)PDGFR (4)PDK1 (2)PEGn (1)PERK (2)PGE synthase (2)Phosphodiesterase (PDE) (9)Phospholipase (4)PI3K (32)PI4K (2)Piezo Channel (1)PIKfyve (3)Pim (9)PKC (12)PKD (1)Plasminogen Activator Inhibitor-1 (PAI-1) (3)Polo-like Kinase (PLK) (4)Porcupine (3)Potassium Channel (13)PPAR (13)Pregnane X Receptor (PXR) (1)Progesterone Receptor (2)Prostaglandin Receptor (11)Prostate Cancer (7)PROTACs (35)Protease-activated Receptor (PAR) (3)Proteasome (12)Protein Disulfide Isomerase (PDI) (1)Protein Phosphatase/PTP (6)Proton Pump (1)Psoriasis (5)RAD51 (1)Radioligand precursors (15)Raf (18)RAR/RXR (3)Ras (17)Renin (2)RET Tyrosine Kinase (c-RET) (3)Rheumatoid Arthritis (16)Ribosomal S6 Kinase (RSK) (5)RIG-I-like Receptor (RLR) (2)RIP kinase (7)ROCK (12)ROR (2)RSV (4)RSV Infection (3)RUNX1-CBFβ (1)S-nitrosoglutathione reductase (GSNOR) (1)Saccharides and Glycosides (1)Salt Inducible Kinase (SIK) (2)SARS-CoV (16)SARS-CoV Infection (34)Schizophrenia (4)Sexual Dysfunction (1)SGLT (4)Sigma Receptor (4)Sirtuin (9)Skin Cancer (13)Sleep Disorder (7)SMN2 Modulator (1)Smoothened (Smo) (9)Sodium Channel (12)Solid Tumors (35)Somatostatin Receptor (2)Sphingosine kinase (SphK) (2)Src (7)STAT (5)Stearoyl-CoA Desaturase (SCD) (1)Steatohepatitis (7)Sterol lipids (1)STING (14)Syk (6)T Cell Receptor (TCR) (1)TAK1 (2)TAM Receptor (Tyro3-Axl-Mer) (4)Taste Receptor (1)Telomerase (2)TGF beta Receptor (TGFBR) (12)Thrombin (3)Thrombosis (13)Thyroid Cancer (1)Thyroid Hormone Receptor (THR) (1)Thyrotropin Receptor (2)TNIK (1)Toll-like Receptor (TLR) (2)TOPK (1)Topoisomerase (11)TRAIL (1)Translocator Protein (TSPO) (1)Trk Receptor (4)TRP Channel (13)Tryptophan Hydroxylase (TPH) (1)Ubiquitin-activating Enzyme (E1) (2)Ubiquitin-conjugating Enzyme (E2) (2)Ulcer (1)ULK (3)Vasopressin Receptor (2)VEGFR (25)Vitamin D Receptor (VDR) (3)Wee1 (1)WNK Kinase (1)Wnt (5)Yes-associated Protein (YAP) (4)γ-secretase (5)

Cart

Request quotation